Avonex (recombinant IFN-β-1a) / Biogen 
Welcome,         Profile    Billing    Logout  

19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
ACTRN12607000184471: Avonex dose titration study in Multiple Sclerosis

Not yet recruiting
4
90
 
Biogen Idec Australia Pty Ltd, Biogen Idec Australia Pty Ltd
Multiple Sclerosis
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann

Ongoing
4
50
Europe
Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia
Medizinische Universität Innsbruck, ABIRISK
Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders"

Ongoing
4
300
Europe
Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE
OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency
Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
04/30
09/30
2006-004937-13: multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis

Ongoing
3
360
Europe
AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG, AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG
Universita di Firenze
patients with relapsing remitting multiple sclerosis
 
 
2008-007162-32: ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS

Ongoing
3
50
Europe
COPAXONE, AVONEX, COPAXONE, AVONEX
ISTITUTO C. MONDINO
Multiple Sclerosis
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
CONNECT, NCT02283853 / 2013-002318-11: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
3
156
Europe, Canada, US, RoW
dimethyl fumarate, BG00012, Tecfidera, Interferon β-1a, Avonex
Biogen
Relapsing-Remitting Multiple Sclerosis
09/25
09/25
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
07/24
05/27
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT00676715 / 2007-006338-32: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Checkmark
Mar 2013 - Mar 2013: 
Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Checkmark Data AAN (MS)
More
Completed
2
220
Europe, Canada, US, RoW
Placebo, Ocrelizumab, RO4964913, Avonex, Interferon-beta-alpha1
Genentech, Inc., Roche Pharma AG
Multiple Sclerosis, Relapsing-Remitting
03/12
11/23
2016-002180-33: Multiple sclerosis therapy with transdermal myelin peptide stimulation.

Ongoing
2
220
Europe
SMderpept, Avonex, Powder for cutaneous solution, Solution for injection
Centrum Neurologii Krzysztof Selmaj, The National Centre for Research and Development
relapsing-remitting multiple sclerosis, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Not yet recruiting
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Not yet recruiting
N/A
100
Europe
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V.
Multiple Sclerosis (MS)
03/26
03/26
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting
N/A
908
Europe, US
Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
07/32
07/32

Download Options